Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
14. November 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on...
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
14. November 2019 08:30 ET
|
Sienna Biopharmaceuticals, Inc.
-- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
07. Oktober 2019 08:30 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a...
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
17. September 2019 08:30 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a...
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
20. Juni 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield...
Sienna Biopharmaceuticals to Present at BAML Health Care Conference
09. Mai 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
08. Mai 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA)...
Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
21. März 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical...
Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
14. März 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results...
Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
05. März 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
WESTLAKE VILLAGE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield...